NASDAQ · Biotechnology

TBPH (TBPH) Stock

$17.03 +0.00% NASDAQ: TBPH Healthcare

Valuation

MetricValue
Price$17.03
Market Cap$882.64M
P/E Ratio16.05
P/B Ratio3.04
P/S Ratio8.48
EPS (TTM)$2.06
52-Week High$21.03
52-Week Low$13.08
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE19.40%
ROA11.45%
ROCE1.06%
Gross Margin-13.08%
Operating Margin-12.15%
Net Margin51.58%
Debt/Equity0.13
Current Ratio11.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$55.0M$51.0M$57.0M$64.0M$107.0M
Operating Profit$-258.0M$-92.0M$-56.0M$-47.0M$-13.0M
Net Profit$-199.0M$872.0M$-55.0M$-56.0M$106.0M
EPS$-2.87$-1.26$-1.00$-1.15$2.06
Op Margin-466.1%-179.1%-97.6%-72.9%-12.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$375.0M$607.0M$382.0M$354.0M$486.0M
Total Liabilities$713.0M$166.0M$169.0M$179.0M$189.0M
Cash$90.0M$298.0M$40.0M$38.0M$168.0M
Borrowings$670.0M$52.0M$49.0M$50.0M$75.0M

Latest News

Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing MT Newswires · Jul 2, 2026 Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run Simply Wall St. · Jul 1, 2026 Theravance Stock Down 3% After Zymeworks Announces Buyout Zacks · Jun 30, 2026 Zymeworks agrees to buy Theravance Biopharma for $929m Pharmaceutical Technology · Jun 30, 2026 Sector Update: Healthcare Stocks Higher Late Afternoon MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-208.0M$-187.0M$-27.0M$-12.0M$239.0M
Investing Cash Flow$121.0M$1.2B$-35.0M$12.0M$-105.0M
Financing Cash Flow$-6.0M$-127.0M$-199.0M$-3.0M$-4.0M
Net Cash Flow$8.0M$208.0M$-259.0M$-2.0M$130.0M
Free Cash Flow$-211.0M$-188.0M$-29.0M$-12.0M$238.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA10.28
FCF Yield5.86%
Quick Ratio13.54
Interest Coverage4.03
Return 1Y49.20%
Return 3Y74.53%
Return 5Y24.23%

Ownership

Insiders Held4.68%
Institutions Held98.22%
Institutions Float Held103.05%
Institutional HolderSharesReport Date
Madison Avenue Partners, LP9,511,1502026-03-31
Weiss Asset Management Lp7,457,0602026-03-31
Newtyn Management, Llc4,841,6292026-03-31
Blackrock Inc.4,296,2902026-03-31
Irenic Capital Management LP 2,760,9482026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $343.46 +0.43% 38.93 $5.01T 0.32%
MSFTMicrosoft Corporation $529.05 -1.93% 28.68 $3.93T 0.76%
GOOGLAlphabet Inc. $340.59 -2.47% 16.94 $4.15T 0.26%
AMZNAmazon.com, Inc. $250.00 -1.87% 19.82 $2.70T 0.00%
METAMeta Platforms, Inc. $709.33 -3.72% 27.93 $1.81T 0.28%

About TBPH

TBPH is led by CEO Rick E. Winningham, employs 97 people, headquartered in US, publicly traded since 2014.

TBPH stock trades at $17.03 with a market capitalization of $882.64M. The stock is valued at a price-to-earnings (P/E) ratio of 16.05, price-to-book of 3.04, price-to-sales of 8.48. Over the past 52 weeks the stock has ranged between $13.08 and $21.03, and currently trades 19.0% below its 52-week high.

On profitability, TBPH generates a return on equity (ROE) of 19.40%, above the typical market range of roughly 12-15%, return on capital employed of 1.06%, an operating margin of -12.15%, a net profit margin of 51.58%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1257.03 +0.43% JNJ Johnson & Johnson $255.56 +0.90% ABBV AbbVie Inc. $285.42 +0.71% UNH UnitedHealth Group Incorporated Common Stock (DE) $401.43 -1.29% MRK Merck & Company, Inc. Common Stock (new) $145.97 +0.53% NVS Novartis AG $150.62 +0.16% AZN AstraZeneca PLC $165.41 -0.76% TMO Thermo Fisher Scientific Inc $690.00 -0.93% AMGN Amgen Inc. $432.49 -0.35% GILD Gilead Sciences, Inc. $156.19 -0.75% ABT Abbott Laboratories $104.88 +0.19% NVO Novo Nordisk A/S $38.83 -0.99%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.